Control Bionics to Issue 7.5 Million Shares for Neuro Elite Athletics Buyout
Control Bionics Limited is set to acquire the remaining stake in Neuro Elite Athletics, integrating the NeuroBounce athletic performance program with its EMG technology to accelerate growth in key markets.
- Acquisition of remaining 77.83% of Neuro Elite Athletics for US$389,150
- Transaction funded by issuing approximately 7.5 million Control Bionics shares
- NeuroBounce program to be integrated with Control Bionics’ NeuroStrip EMG platform
- Expansion focus on U.S. and Australian high-growth athletic performance markets
- Completion targeted for late December 2025, subject to due diligence
Strategic Acquisition to Consolidate Control
Control Bionics Limited, a medical device company specialising in wearable electromyography (EMG) technology, has announced plans to acquire full ownership of Neuro Elite Athletics LLC, the U.S.-based company behind the NeuroBounce athletic performance program. This move follows Control Bionics’ initial investment in 2024 and represents a significant step in consolidating its presence in the sports performance sector.
The acquisition values Neuro Elite Athletics at US$500,000, with Control Bionics acquiring the remaining 77.83% stake for US$389,150. Rather than a cash transaction, the deal will be funded through the issuance of approximately 7.5 million Control Bionics shares, equating to about 1.9% of the company’s issued capital based on recent share prices. These shares will be escrowed for 12 months, reflecting a cautious approach to shareholder value preservation.
Integrating Technology and Market Expansion
The NeuroBounce program leverages neuromuscular activation strategies to enhance athletic explosiveness, muscle power, and jumping ability, using EMG-driven tools to provide measurable performance improvements. Control Bionics plans to integrate NeuroBounce with its NeuroStrip technology, a miniaturised, wearable EMG device designed to open new markets in health diagnostics, sports performance, and rehabilitation.
By bringing NeuroBounce fully under its umbrella, Control Bionics aims to accelerate product rollout and deepen engagement with performance coaches and athletes in both the U.S. and Australia. The acquisition also includes all intellectual property, staff, and assets of Neuro Elite Athletics, enabling tighter operational and technological integration.
Leadership Perspectives and Future Outlook
Jeremy Steele, CEO of Control Bionics, highlighted the promising traction NeuroBounce has gained and emphasised the strategic importance of full ownership to streamline growth efforts. Steve Bennett, founder of Neuro Elite Athletics, expressed enthusiasm about joining the Control Bionics family, noting the complementary strengths of the two companies and the potential for accelerated innovation.
Completion of the acquisition is targeted for late December 2025, pending confirmatory due diligence and final contract execution. This timeline suggests that investors should watch closely for updates on integration progress and market response in the coming months.
Bottom Line?
Control Bionics’ full acquisition of NeuroBounce sets the stage for accelerated innovation and market expansion in athletic performance technology.
Questions in the middle?
- How will the integration of NeuroBounce and NeuroStrip technologies impact product development timelines?
- What are the anticipated revenue contributions from the NeuroBounce program post-acquisition?
- How might the share issuance affect Control Bionics’ capital structure and investor sentiment?
